Exercise is not categorically off-limits in HCM — stimulants are a separate question
In short
In hypertrophic cardiomyopathy (HCM), exercise is not categorically contraindicated. Sympathomimetic drugs, by contrast, remain a separate judgement in structural heart disease. The patient in this case report was a 26-year-old man diagnosed at 16, with a decade of imaging showing stable septal hypertrophy, preserved systolic function and no high-risk features. His ECG showed left ventricular hypertrophy and repolarisation abnormalities, and QT dispersion of 74 ms, below high-risk thresholds reported in HCM cohorts. After counselling on arrhythmic risk and possible ECG surveillance, he declined the stimulant, chose psychotherapy, and kept training.
Start with the case. A 26-year-old man, diagnosed with hypertrophic cardiomyopathy at 16, referred for an assessment of whether methylphenidate was safe for his ADHD while on paroxetine for social anxiety. Ten years of cardiac imaging showed stable septal hypertrophy, preserved systolic function and no high-risk features. The ECG showed left ventricular hypertrophy and repolarisation abnormalities, with QT dispersion of 74 ms.
What makes the case interesting is not the conclusion but that the question splits in two. One is whether he can exercise. The other is whether he can take a drug that stimulates the sympathetic nervous system. The two answers do not move together.
Why is exercise not categorically contraindicated?
The report states it outright in its background: exercise is not categorically contraindicated in HCM. Blanket restriction has been eroded by data. In a pooled dataset of 205 HCM patients, training raised peak oxygen uptake, and adding resistance work was no worse than endurance alone — covered in exercise in hypertrophic cardiomyopathy.
So why is a stimulant different arithmetic?
Exercise creates a temporary, predictable sympathetic load whose intensity and duration the person controls. A stimulant creates a load that runs for the drug's half-life and cannot be switched off midway. On top of that, as the report notes, evidence on stimulant-related arrhythmic risk in low-risk HCM is limited. Thin evidence cannot produce a general rule, which leaves individualised assessment.
What does a number like 74 ms of QT dispersion do?
Numbers like this are material for risk stratification, not answers. This patient's 74 ms sat below high-risk thresholds reported in HCM cohorts and, alongside a decade of stable imaging, placed him on the low-risk side. The point is that no conclusion followed automatically — low risk was a condition that opened options, not a clearance.
How much left ventricular hypertrophy an ECG actually catches, and what that finding predicts, are covered in the limits of ECG voltage criteria and ECG left ventricular hypertrophy and sudden death.
What does this case mean for a lifter?
Being told you can train with a cardiac diagnosis is not the same answer as you can take a stimulant. Pre-workout supplements, high-dose caffeine and prescription stimulants all raise the same class of question, and in this case that question was handled as something to calculate with the treating clinician. In the end the patient did not take the drug, and did keep training.
- Clearance to train and clearance to medicate are separate decisions — passing one does not carry the other.
- Judge supplements by ingredient — the stimulant compound and its dose are the object of the decision, not the product name.
- Low risk is not an exemption — ECG surveillance stayed on the table even after the low-risk read.
- Declining the drug is also a conclusion — this patient moved to psychotherapy-based management and kept his training.
This is a single case report, not a practice guideline. With hypertrophic cardiomyopathy or any structural heart disease, training intensity, exercise selection and any stimulant-containing supplement are decisions for the treating clinician. Syncope, chest pain, severe breathlessness during exertion, or a family history of sudden death at a young age are not things to self-assess.
Frequently asked questions
Does hypertrophic cardiomyopathy rule out exercise?
Not categorically. The background to this case report states explicitly that exercise is not categorically contraindicated in HCM, and the patient continued exercising after counselling. Intensity and exercise selection still follow from an individual risk assessment.
Why do stimulants need a separate judgement?
Concerns persist about sympathomimetic agents in structural heart disease, and evidence on stimulant-related arrhythmic risk specifically in low-risk HCM is limited. Where evidence is thin, individualised assessment replaces a general rule.
What does 74 ms of QT dispersion mean?
QT dispersion is an ECG measure of non-uniform ventricular repolarisation used in risk stratification. This patient's 74 ms fell below high-risk thresholds reported in hypertrophic cardiomyopathy cohorts and, with a decade of stable imaging, was read as low risk.
What did the patient decide?
After counselling on arrhythmic risk and the possibility of ECG surveillance, he declined methylphenidate and moved to psychotherapy-based management of his ADHD while continuing to exercise.
Do pre-workout supplements raise the same issue?
This case concerned a prescription stimulant rather than a supplement. Stimulant-containing pre-workouts and high-dose caffeine do raise the same class of question, so with structural heart disease they are worth checking with the treating clinician by ingredient and dose rather than by product name.
Source: PubMed